




JUNTA GENERAL DE ACCIONISTAS

Aquí encontramos la portada del documento “Notice of anual meeting of shareholders and proxy statement 2022”, que podemos visitar a continuación y de donde se ha extraído la información requerida:

<https://www.abbottinvestor.com/static-files/a766155d-5d3a-4d48-9b3d-b8455e0872cd>



PROXY STATEMENT

Es un documento proporcionado por las corporaciones públicas para que sus accionistas puedan entender cómo votar en las asambleas de accionistas y tomar decisiones informadas sobre cómo delegar sus votos a un apoderado.

NOTICE OF 2022 ANNUAL MEETING OF SHAREHOLDERS

Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on April 29, 2022

The Annual Meeting of the Shareholders of Abbott Laboratories will be held on Friday, April 29, 2022, at 9:00 a.m. Central Time.

The 2022 Annual Meeting of Shareholders will be held virtually to enable broader and more convenient shareholder participation and to support the health and safety of Abbott's shareholders, employees, and communities during the ongoing coronavirus pandemic. There will not be a physical location for the Annual Meeting, and shareholders will not be able to attend the Annual Meeting in person.

Shareholders of record as of the close of business on March 2, 2022 will be able to attend the Annual Meeting at meetnow.global/ABT2022. To be admitted to the Annual Meeting, shareholders will be required to enter a 15-digit control number. Shareholders who wish to attend the meeting on a listen-only phone line should contact Abbott representatives at 224-668-7238 or abbotshareholders@abbott.com to obtain the meeting telephone number in advance of the meeting. Please see page 90 for further instructions on how to be admitted to the Annual Meeting.

Shareholders will be asked to vote on the following items of business:

Agenda	Board Voting Recommendation
Item 1 Election of the 12 director nominees named in this proxy statement to hold office until the next Annual Meeting or until the next meeting of shareholders at which directors are elected	FOR Each Director Nominee
Item 2 Ratification of the appointment of Ernst & Young LLP as auditors of Abbott for 2022	FOR
Item 3 Approval, on an advisory basis, of executive compensation	FOR
Items 4-8 Five shareholder proposals, if properly presented at the meeting	AGAINST

Shareholders will also transact such other business as may properly come before the meeting, including any adjournment or postponement thereof.

This proxy statement and the accompanying proxy card, and the Notice of Internet Availability of Proxy Materials, are being provided to shareholders on or about March 18, 2022.

Abbott's 2022 Proxy Statement and 2021 Annual Report to Shareholders are available at www.abbott.com/proxy.

YOUR VOTE IS IMPORTANT

Please sign and promptly return your proxy or voting instruction form in the enclosed envelope, or vote your shares by telephone or using the Internet.

If you are a registered shareholder (you received your proxy materials from Abbott through Abbott's transfer agent, Computershare), you may vote your shares by telephone (1-800-652-VOTE (8683)) or on the Internet at www.investorvote.com/abt.

If you are a beneficial shareholder (you received your proxy materials from a broker, bank, or other agent), please refer to the voting instructions provided to you by your broker, bank, or other agent.

By order of the Board of Directors.

HUBERT L. ALLEN
Secretary

March 18, 2022

2 

Podemos ver que la "Annual Meeting of the Shareholders of Abbott Laboratories", se llevará a cabo el viernes 29 de abril de 2022.

TABLE OF CONTENTS

	PAGE		PAGE
Notice of 2022 Annual Meeting of Shareholders.....	2	Shareholder Proposals.....	73
Proxy Summary.....	3	Shareholder Proposal on Special Shareholder Meeting Threshold (Item 4 on Proxy Card).....	73
Nominees for Election as Directors (Item 1 on Proxy Card).....	10	Shareholder Proposal on Independent Board Chairman (Item 5 on Proxy Card).....	75
The Board of Directors and Its Committees.....	16	Shareholder Proposal on Rule 10b5-1 Plans (Item 6 on Proxy Card).....	78
The Board of Directors.....	16	Shareholder Proposal on Lobbying Disclosure (Item 7 on Proxy Card).....	80
Leadership Structure.....	16	Shareholder Proposal on Antimicrobial Resistance Report (Item 8 on Proxy Card).....	83
Board Diversity and Composition.....	18	Additional Information.....	86
Director Selection.....	19	Security Ownership of Executive Officers and Directors.....	86
Board Oversight.....	20	Information Concerning Security Ownership.....	87
Committees of the Board of Directors.....	21	Approval Process for Related Person Transactions.....	87
Shareholder Engagement.....	24	Date for Receipt of Shareholder Proposals for the 2023 Annual Meeting Proxy Statement.....	88
Board Evaluation Process.....	24	Procedure for Recommendation and Nomination of Directors and Transaction of Business at Annual Meeting.....	88
Communicating with the Board of Directors.....	25	General.....	89
Corporate Governance Materials.....	25	Information About the Annual Meeting.....	90
Director Compensation.....	26	Cautionary Statement Regarding Forward-Looking Statements.....	94
Executive Compensation.....	28	Exhibit A—Director Independence Standard.....	A-1
Compensation Discussion and Analysis.....	28		
Compensation Committee Report.....	51		
Compensation Risk Assessment.....	52		
Summary Compensation Table.....	54		
2021 Grants of Plan Based Awards.....	57		
2021 Outstanding Equity Awards at Fiscal Year End.....	58		
2021 Option Exercises and Stock Vested.....	61		
Pension Benefits.....	61		
Potential Payments Upon Termination or Change in Control.....	65		
CEO Pay Ratio.....	68		
Ratification of Ernst & Young LLP as Auditors (Item 2 on Proxy Card).....	69		
Report of the Audit Committee.....	70		
Say on Pay—An Advisory Vote on the Approval of Executive Compensation (Item 3 on Proxy Card).....	71		

Aquí podemos encontrar el Form 10-K que nos brinda un resumen del desempeño financiero de la compañía:

<https://sec.report/Document/0001104659-22-025141/>

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-K		
<small>(MARK ONE)</small>		
<input checked="" type="checkbox"/>	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934	OR
<input type="checkbox"/>	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934	
<small>For the fiscal year ended December 31, 2021</small>		<small>Commission file number 1-2189</small>
Abbott Laboratories		
<small>An Illinois Corporation 100 Abbott Park Road Abbott Park, Illinois 60064-6000</small>		<small>36-6088409 (I.R.S. employer identification number) (224) 667-6100 (telephone number)</small>
<small>Securities Registered Pursuant to Section 12(b) of the Act:</small>		
<small>Title of Each Class</small>	<small>Trading Symbol(s)</small>	<small>Name of Each Exchange on Which Registered</small>
Common Shares, Without Par Value	ABT	New York Stock Exchange Chicago Stock Exchange, Inc.
<small>Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</small>		
Yes <input checked="" type="checkbox"/>		No <input type="checkbox"/>
<small>Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.</small>		
Yes <input type="checkbox"/>		No <input checked="" type="checkbox"/>
<small>Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</small>		
Yes <input checked="" type="checkbox"/>		No <input type="checkbox"/>
<small>Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</small>		
Yes <input checked="" type="checkbox"/>		No <input type="checkbox"/>
<small>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</small>		
<small>Large Accelerated Filer</small> <input checked="" type="checkbox"/>	<small>Accelerated Filer</small> <input type="checkbox"/>	<small>Non-Accelerated Filer</small> <input type="checkbox"/>
		<small>Smaller reporting company</small> <input type="checkbox"/> <small>Emerging growth company</small> <input type="checkbox"/>
<small>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</small> <input type="checkbox"/>		
<small>Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7242(b)) by the registered public accounting firm that prepared or issued its audit report.</small> <input type="checkbox"/>		
<small>Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).</small>		
Yes <input type="checkbox"/>		No <input checked="" type="checkbox"/>

CONSEJO DE ADMINISTRACIÓN

Aquí vemos “The board of Directors”, donde figura el nombre los miembros, así como del presidente. En la tabla podemos ver para cada uno, datos como, su principal ocupación, su edad o de que comité son miembros.


DIRECTOR NOMINEES

The Board of Directors recommends a vote **FOR** the election of each of the following nominees for director. All nominees are currently serving as directors. Additional information about each director nominee’s background and experience can be found beginning on page 10.

Name	Principal Occupation	Age	Director Since	Committee Memberships
ROBERT J. ALPERN, M.D. Independent	Professor and Former Dean, Yale School of Medicine	71	2008	<ul style="list-style-type: none"> • Nominations and Governance • Public Policy
SALLY E. BLOUNT, PH.D. Independent	President and CEO, Catholic Charities of the Archdiocese of Chicago, and Professor and Former Dean, J.L. Kellogg Graduate School of Management	60	2011	<ul style="list-style-type: none"> • Nominations and Governance • Public Policy
ROBERT B. FORD	Chairman of the Board and Chief Executive Officer, Abbott Laboratories	48	2019	<ul style="list-style-type: none"> • Executive (Chair)
PAOLA GONZALEZ Independent	Vice President and Treasurer, The Clorox Company	50	2021	<ul style="list-style-type: none"> • Audit
MICHELLE A. KUMBIER Independent	President, Turf & Consumer Products, Briggs & Stratton, LLC	54	2018	<ul style="list-style-type: none"> • Audit • Compensation
DARREN W. McDEW Independent	Retired General, U.S. Air Force, and Former Commander of U.S. Transportation Command	61	2019	<ul style="list-style-type: none"> • Nominations and Governance • Public Policy
NANCY McKINSTRY Independent	CEO and Chairman of the Executive Board, Wolters Kluwer N.V.	63	2011	<ul style="list-style-type: none"> • Audit (Chair) • Compensation • Executive
WILLIAM A. OSBORN Lead Independent Director	Retired Chairman and CEO, Northern Trust Corporation	74	2008	<ul style="list-style-type: none"> • Compensation • Nominations and Governance (Chair) • Executive
MICHAEL F. ROMAN Independent	Chairman, President, and CEO, 3M Company	62	2021	<ul style="list-style-type: none"> • Audit • Compensation
DANIEL J. STARKS Independent	Retired Chairman, President and CEO, St. Jude Medical, Inc.	67	2017	<ul style="list-style-type: none"> • Public Policy
JOHN G. STRATTON Independent	Executive Chairman, Frontier Communications Parent, Inc.	61	2017	<ul style="list-style-type: none"> • Audit • Public Policy
GLENN F. TILTON Independent	Retired Chairman, President and CEO, UAL Corporation	73	2007	<ul style="list-style-type: none"> • Audit • Public Policy (Chair) • Executive

A continuación, encontramos “The board diversity”, donde apreciaríamos un 33% de mujeres.

BOARD DIVERSITY



COMITÉS

COMMITTEES OF THE BOARD OF DIRECTORS

The Board of Directors has five committees established in Abbott's By-Laws: Audit Committee, Compensation Committee, Nominations and Governance Committee, Public Policy Committee, and Executive Committee.

All members of the Audit Committee, Compensation Committee, Nominations and Governance Committee, and Public Policy Committee are independent. These Committees are governed by written charters setting forth their respective responsibilities, and each Committee reviews its charter at least annually, with any changes being recommended to the full Board for approval. Copies of the Committee charters are all available in the governance section of Abbott's investor relations website (www.abbottinvestor.com).

	COMMITTEE MEMBERSHIPS				
	Audit Committee*	Compensation Committee†	Nominations and Governance Committee	Public Policy Committee	Executive Committee
Current Members					
Robert J. Alpern, M.D.			●	●	
Roxanne S. Austin		○	●		●
Sally E. Blount, Ph.D.			●	●	
Robert B. Ford					○
Paola Gonzalez	●				
Michelle A. Kumbier	●	●			
Darren W. McDew			●	●	
Nancy McKinstry	○	●			●
William A. Osborn		●	○		●
Michael F. Roman	●	●			
Daniel J. Starks				●	
John G. Stratton	●			●	
Glenn F. Tilton	●			○	●
Total Meetings Held in 2021	7	4	5	4	0

○ Chair ● Member

* Each of the committee members is financially literate, as is required of audit committee members by the New York Stock Exchange. The Board of Directors has determined that Nancy McKinstry is an "audit committee financial expert."

† Ms. Austin is not standing for re-election at the Annual Meeting. The Board of Directors will appoint a new Compensation Committee chair upon conclusion of her tenure at the Annual Meeting.

Los distintos comités existentes son:

- Audit Committee.
- Compensation Committee.
- Nominations and Governance Committee.
- Public Policy Committee y Executive Committee.

En ellos vemos marcados para cada uno de los miembros como "Chair" o "Member".

ESTRUCTURA ORGANIZATIVA (ORGANIGRAMA)

Extraído de:

<https://www.theofficialboard.es/organigrama/abbott>



Robert B. Ford es un hombre de negocios estadounidense y el decimotercer director ejecutivo. Recibió una licenciatura de Boston College y un master en administración de empresas de la Escuela de Negocios Haas de la Universidad de California, Berkeley .

Se unió a Abbott en **1996** dentro de su negocio de cuidado de la diabetes, luego dirigió los negocios de dispositivos médicos de la compañía y la integración de Abbott de St. Jude Medical en 2017. Fue nombrado **presidente y director de operaciones** en octubre de 2018.

ESCTRUCTURA SOCIETARIA

Sociedades subsidiarias:

- **Abbott** (Spain)
- **Abbott** (Canada)
- **Abbott** Japan
- **Abbott** (South Korea)
- **Abbott** (Germany)
- **Abbott** (United Kingdom)
- **Abbott** Rapid Diagnostics Jena GmbH

Vemos que las distintas filiales pertenecen cada una a un país, por lo que no tendría sentido agruparlas toda dentro de una matriz ya que cada de una de ellas operará en su país correspondiente.

PAULA LUNA GARCÍA